Suppr超能文献

噬菌体作为抗菌剂的特性及效率测试

Characterization and Testing the Efficiency of Phage as an Antibacterial Agent.

作者信息

Kusradze Ia, Karumidze Natia, Rigvava Sophio, Dvalidze Teona, Katsitadze Malkhaz, Amiranashvili Irakli, Goderdzishvili Marina

机构信息

G. Eliava Institute of Bacteriophages, Microbiology and Virology Tbilisi, Georgia.

G. Eliava Institute of Bacteriophages, Microbiology and VirologyTbilisi, Georgia; Ivane Javakhishvili Tbilisi State UniversityTbilisi, Georgia.

出版信息

Front Microbiol. 2016 Oct 4;7:1590. doi: 10.3389/fmicb.2016.01590. eCollection 2016.

Abstract

is a gram-negative, non-motile bacterium that, due to its multidrug resistance, has become a major nosocomial pathogen. The increasing number of multidrug resistant (MDR) strains has renewed interest in phage therapy. The aim of our study was to assess the effectiveness of phage administration in wound infections in an animal model to demonstrate phage therapy as non-toxic, safe and alternative antibacterial remedy. Using classical methods for the study of bacteriophage properties, we characterized phage as a dsDNA myovirus with a 90 kb genome size. Important characteristics of include a short latent period and large burst size, wide host range, resistance to chloroform and thermal and pH stability. In a rat wound model, phage application effectively decreased the number of bacteria isolated from the wounds of successfully treated animals. This study highlights the effectiveness of the phage therapy and provides further insight into treating infections caused by MDR strains using phage administration.

摘要

是一种革兰氏阴性、无运动性的细菌,由于其多重耐药性,已成为主要的医院病原体。多重耐药(MDR)菌株数量的增加重新引发了对噬菌体疗法的兴趣。我们研究的目的是评估在动物模型中噬菌体给药对伤口感染的有效性,以证明噬菌体疗法是无毒、安全的替代抗菌疗法。使用研究噬菌体特性的经典方法,我们将噬菌体鉴定为一种基因组大小为90 kb的双链DNA肌病毒。其重要特征包括潜伏期短、裂解量高、宿主范围广、对氯仿有抗性以及热稳定性和pH稳定性。在大鼠伤口模型中,噬菌体的应用有效地减少了从成功治疗动物伤口分离出的细菌数量。这项研究突出了噬菌体疗法的有效性,并为使用噬菌体给药治疗由多重耐药菌株引起的感染提供了进一步的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd94/5047890/b18d3adc8d6d/fmicb-07-01590-g001.jpg

相似文献

1
Characterization and Testing the Efficiency of Phage as an Antibacterial Agent.
Front Microbiol. 2016 Oct 4;7:1590. doi: 10.3389/fmicb.2016.01590. eCollection 2016.
3
Phage therapy for Acinetobacter baumannii infection.
Prog Mol Biol Transl Sci. 2023;200:303-324. doi: 10.1016/bs.pmbts.2023.04.006. Epub 2023 Jun 27.
5
Efficacy of a phage cocktail in controlling phage resistance development in multidrug resistant Acinetobacter baumannii.
Virus Res. 2019 Oct 15;272:197734. doi: 10.1016/j.virusres.2019.197734. Epub 2019 Aug 26.
10
Characterization of Virulent T4-Like Bacteriophages DLP1 and DLP2.
Viruses. 2023 Mar 13;15(3):739. doi: 10.3390/v15030739.

引用本文的文献

1
Genomic characterization and pre-clinical evaluation of a new polyvalent lytic Loughborough phage.
Appl Microbiol Biotechnol. 2025 Aug 2;109(1):177. doi: 10.1007/s00253-025-13559-2.
2
Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.
Mol Biotechnol. 2025 Jul 9. doi: 10.1007/s12033-025-01466-w.
4
Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii.
AMB Express. 2025 Mar 12;15(1):44. doi: 10.1186/s13568-025-01837-1.
5
Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens.
Antibiotics (Basel). 2025 Jan 9;14(1):63. doi: 10.3390/antibiotics14010063.
8
Treatment of infections caused by carbapenem-resistant .
Front Cell Infect Microbiol. 2024 Jul 18;14:1395260. doi: 10.3389/fcimb.2024.1395260. eCollection 2024.
9
A Novel and Effective Therapeutic Method for Treating Infection in .
Animals (Basel). 2024 Mar 19;14(6):957. doi: 10.3390/ani14060957.
10
Characterization of a  phage vB_AbaM-SHI and its inhibition effect on biofilms of .
Front Cell Infect Microbiol. 2024 Mar 8;14:1351993. doi: 10.3389/fcimb.2024.1351993. eCollection 2024.

本文引用的文献

1
Acinetobacter baumannii: biology and drug resistance - role of carbapenemases.
Folia Histochem Cytobiol. 2016;54(2):61-74. doi: 10.5603/FHC.a2016.0009. Epub 2016 Jun 8.
2
Spread of carbapenem-resistant international clones of Acinetobacter baumannii in Turkey and Azerbaijan: a collaborative study.
Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1463-8. doi: 10.1007/s10096-016-2685-x. Epub 2016 Jun 4.
3
Colistin-resistant Acinetobacter baumannii ventilator-associated pneumonia in a tertiary care hospital: an evolving threat.
J Hosp Infect. 2016 Sep;94(1):72-3. doi: 10.1016/j.jhin.2016.04.014. Epub 2016 May 6.
4
Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study.
Ann Saudi Med. 2016 May-Jun;36(3):216-22. doi: 10.5144/0256-4947.2016.216.
6
Intranasal treatment with bacteriophage rescues mice from Acinetobacter baumannii-mediated pneumonia.
Future Microbiol. 2016 May;11:631-41. doi: 10.2217/fmb.16.11. Epub 2016 Feb 29.
9
Isolation and characterisation of lytic bacteriophages of Klebsiella pneumoniae and Klebsiella oxytoca.
Curr Microbiol. 2013 Mar;66(3):251-8. doi: 10.1007/s00284-012-0264-7. Epub 2012 Nov 11.
10
Isolation and characterization of wide host range lytic bacteriophage AP22 infecting Acinetobacter baumannii.
FEMS Microbiol Lett. 2012 Jul;332(1):40-6. doi: 10.1111/j.1574-6968.2012.02573.x. Epub 2012 May 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验